
|Videos|December 14, 2017
Dr. Mileham Discusses Biomarkers in Lung Cancer
Author(s)Kathryn Mileham, MD
Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.
Advertisement
Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.
The landscape of lung cancer has changed tremendously over the past 20 years, says Mileham. With the discovery of numerous mutations, the development of biomarkers and biomarker testing has blossomed.
Mileham says that the established biomarkers that are predictive in response for non—small cell lung cancer are ALK, ROS1, EGFR, BRAF, and PD-L1.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































